Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)

Ph+ (BCR::ABL+) B-ALL was considered to be high risk, but recent advances in BCR::ABL-targeting TKIs has shown improved outcomes in combination with backbone chemotherapy. Nevertheless, new treatment strategies are needed, including approaches without chemotherapy for elderly patients. LIMK1/2 acts...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrou, Jeannig, Dupont, Mélanie, Djamai, Hanane, Adicéam, Emilie, Parietti, Véronique, Kaci, Anna, Clappier, Emmanuelle, Cayuela, Jean-Michel, Baruchel, André, Paublant, Fabrice, Prudent, Renaud, Ghysdael, Jacques, Gardin, Claude, Dombret, Hervé, Braun, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692768/
https://www.ncbi.nlm.nih.gov/pubmed/36431240
http://dx.doi.org/10.3390/jcm11226761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692768/
https://www.ncbi.nlm.nih.gov/pubmed/36431240
http://dx.doi.org/10.3390/jcm11226761

Ejemplares similares